Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines

Virology

Volumn 284, Issue 1, 2001, Pages 46-61

  Kjerrström, Anne ^a   Hinkula, Jorma ^a   Engström, Gunnel ^a   Ovod, Vladimir ^b   Krohn, Kai ^b   Benthin, Reinhold ^a   Wahren, Britta ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF TAMPERE   (Finland)

Author keywords

DNA immunization; Gene interaction; HIV; Nef; Protein interaction; Regulatory genes; Rev; Tat

Indexed keywords

DNA VACCINE; NEF PROTEIN; REV PROTEIN; TRANSACTIVATOR PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; GENE NEF; GENE REV; GENE TAT; GENETIC CODE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATOR GENE; T LYMPHOCYTE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0035947281     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2001.0905     Document Type: Article

References (40)

1. Aiken C., Krause L., Chen Y. L., Trono D. Mutational analysis of HIV-1 Nef: identification of two mutants that are temperature-sensitive for CD4 downregulation. Virology. 217:1996;293-300.
2. Ayyavoo V., Kudchodkar S., Ramanathan M. P., Le P., Muthumani K., Megalai N. M., Dentchev T., Santiago-Barrios L., Mrinalini C., Weiner D. B. Immunogenicity of a novel DNA vaccine cassette expressing multiple human immunodeficiency virus (HIV-1) accessory genes. Aids. 14:2000;1-9.
3. Behboudi S., Chao D., Klenerman P., Austyn J. The effects of DNA containing CpG motif on dendritic cells. Immunology. 99:2000;361-366.
4. Bieniasz P. D., Grdina T. A., Bogerd H. P., Cullen B. R. Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. EMBO J. 17:1998;7056-7065.
5. Braun R., Babiuk L. A., van Drunen Littel-van den Hurk S. Compatibility of plasmids expressing different antigens in a single DNA vaccine formulation. J. Gen. Virol. 79:1998;2965-2970.
6. Cafaro A., Caputo A., Fracasso C., Maggiorella M. T., Goletti D., Baroncelli S., Pace M., Sernicola L., Koanga-Mogtomo M. L., Betti M., Borsetti A., Belli R., Akerblom L., Corrias F., Butto S., Heeney J., Verani P., Titti F., Ensoli B. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine [see comments]. Nat. Med. 5:1999;643-650.
7. Calarota S., Bratt G., Nordlund S., Hinkula J., Leandersson A. C., Sandström E., Wahren B. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet. 351:1998;1320-1325.
8. Calarota S. A., Leandersson A. C., Bratt G., Hinkula J., Klinman D. M., Weinhold K. J., Sandström E., Wahren B. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. J. Immunol. 163:1999;2330-2338.
9. Cardoso A. I., Sixt N., Vallier A., Fayolle J., Buckland R., Wild T. F. Measles virus DNA vaccination: antibody isotype is determined by the method of immunization and by the nature of both the antigen and the coimmunized antigen. J. Virol. 72:1998;2516-2518.
10. Cohen G. B., Gandhi R. T., Davis D. M., Mandelboim O., Chen B. K., Strominger J. L., Baltimore D. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity. 10:1999;661-671.
11. Donnelly J. J., Ulmer J. B., Shiver J. W., Liu M. A. DNA vaccines. Annu. Rev. Immunol. 15:1997;617-648.
12. Feinberg M. B., Greene W. C. Molecular insights into human immunodeficiency virus type 1 pathogenesis. Curr. Opin. Immunol. 4:1992;466-474.
13. Fritz C. C., Zapp M. L., Green M. R. A human nucleoporin-like protein that specifically interacts with HIV Rev. Nature. 376:1995;530-533.
14. Greenway A. L., McPhee D. A., Grgacic E., Hewish D., Lucantoni A., Macreadie I., Azad A. Nef 27, but not the Nef 25 isoform of human immunodeficiency virus-type 1 pNL4.3 down-regulates surface CD4 and IL-2R expression in peripheral blood mononuclear cells and transformed T cells. Virology. 198:1994;245-256.
15. Grifantini R., Finco O., Bartolini E., Draghi M., Del Giudice G., Kocken C., Thomas A., Abrignani S., Grandi G. Multi-plasmid DNA vaccination avoids antigenic competition and enhances immunogenicity of a poorly immunogenic plasmid. Eur. J. Immunol. 28:1998;1225-1232.
16. Harris M. From negative factor to a critical role in virus pathogenesis: the changing fortunes of Nef. J. Gen. Virol. 77:1996;2379-2392.
17. Hartmann G., Krieg A. M. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J. Immunol. 164:2000;944-953.
18. Hinkula J., Lundholm P., Wahren B. Nucleic acid vaccination with HIV regulatory genes: a combination of HIV-1 genes in separate plasmids induces strong immune responses. Vaccine. 15:1997a;874-878.
19. Hinkula J., Svanholm C., Schwartz S., Lundholm P., Brytting M., Engstrom G., Benthin R., Glaser H., Sutter G., Kohleisen B., Erfle V., Okuda K., Wigzell H., Wahren B. Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes. J. Virol. 71:1997b;5528-5539.
20. Huang L., Li C. J., Pardee A. B. Human immunodeficiency virus type 1 TAT protein activates B lymphocytes. Biochem. Biophys. Res. Commun. 237:1997;461-464.
21. Khan I. H., Sawai E. T., Antonio E., Weber C. J., Mandell C. P., Montbriand P., Luciw P. A. Role of the SH3-ligand domain of simian immunodeficiency virus Nef in interaction with Nef-associated kinase and simian AIDS in rhesus macaques. J. Virol. 72:1998;5820-5830.
22. Klinman D. M., Barnhart K. M., Conover J. CpG motifs as immune adjuvants. Vaccine. 17:1999;19-25.
23. MacGregor R. R., Boyer J. D., Ugen K. E., Lacy K. E., Gluckman S. J., Bagarazzi M. L., Chattergoon M. A., Baine Y., Higgins T. J., Ciccarelli R. B., Coney L. R., Ginsberg R. S., Weiner D. B. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response. J. Infect. Dis. 178:1998;92-100.
24. McClements W. L., Armstrong M. E., Keys R. D., Liu M. A. Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. Proc. Natl. Acad. Sci. USA. 93:1996;11414-11420.
25. Mermer B., Felber B. K., Campbell M., Pavlakis G. N. Identification of trans-dominant HIV-1 rev protein mutants by direct transfer of bacterially produced proteins into human cells. Nucleic Acids Res. 18:1990;2037-2044.
26. Murphy R., Wente S. R. An RNA-export mediator with an essential nuclear export signal. Nature. 383:1996;357-360.
27. Myers G., Korber B., Wain-Hobson S., Jeang K.-T., Henderson L. E., Pavlakis G. N. T. B. a. B. Group. A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. 1994.
28. Osterhaus A. D., van Baalen C. A., Gruters R. A., Schutten M., Siebelink C. H., Hulskotte E. G., Tijhaar E. J., Randall R. E., van Amerongen G., Fleuchaus A., Erfle V., Sutter G. Vaccination with Rev and Tat against AIDS. Vaccine. 17:1999;2713-2714.
29. Ovod V., Lagerstedt A., Ranki A., Gombert F. O., Spohn R., Tähtinen M., Jung G., Krohn K. J. Immunological variation and immunohistochemical localization of HIV-1 Nef demonstrated with monoclonal antibodies. Aids. 6:1992;25-34.
30. Parada C. A., Roeder R. G. A novel RNA polymerase II-containing complex potentiates Tat-enhanced HIV-1 transcription. EMBO J. 18:1999;3688-3701.
31. Piguet V., Trono D. The Nef protein of primate lentiviruses. Rev. Med. Virol. 9:1999;111-120.
32. Puri R. K., Leland P., Aggarwal B. B. Constitutive expression of human immunodeficiency virus type 1 tat gene inhibits interleukin 2 and interleukin 2 receptor expression in a human CD4+ T lymphoid (H9) cell line. AIDS Res. Hum. Retroviruses. 11:1995;31-40.
33. Ranki A., Lagerstedt A., Ovod V., Aavik E., Krohn K. J. Expression kinetics and subcellular localization of HIV-1 regulatory proteins Nef, Tat and Rev in acutely and chronically infected lymphoid cell lines. Arch. Virol. 139:1994;365-378.
34. Robinson H. L., Hunt L. A., Webster R. G. Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine. 11:1993;957-960.
35. Sato Y., Roman M., Tighe H., Lee D., Corr M., Nguyen M. D., Silverman G. J., Lotz M., Carson D. A., Raz E. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science. 273:1996;352-354.
36. Schwartz O., Marechal V., Le Gall S., Lemonnier F., Heard J. M. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat. Med. 2:1996;338-342.
37. Ugen K. E., Nyland S. B., Boyer J. D., Vidal C., Lera L., Rasheid S., Chattergoon M., Bagarazzi M. L., Ciccarelli R., Higgins T., Baine Y., Ginsberg R., Macgregor R. R., Weiner D. B. DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans. Vaccine. 16:1998;1818-1821.
38. Wang R., Doolan D. L., Le T. P., Hedstrom R. C., Coonan K. M., Charoenvit Y., Jones T. R., Hobart P., Margalith M., Ng J., Weiss W. R., Sedegah M., de Taisne C., Norman J. A., Hoffman S. L. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science. 282:1998;476-480.
39. Wei P., Garber M. E., Fang S. M., Fischer W. H., Jones K. A. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell. 92:1998;451-462.
40. Weiner G. J., Liu H. M., Wooldridge J. E., Dahle C. E., Krieg A. M. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. USA. 94:1997;10833-10837.